Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by synovial joint inflammation leading to cartilage destruction and bone erosion. Early diagnosis and treatment is essential to minimise the risk of future joint damage and disability. Treatment options include conventional disease-modifying anti-rheumatic drugs (DMARDS) such as methotrexate, and biological therapies including tumour necrosis factor (TNF) inhibitors and interleukin-6 antagonists. However, some patients fail to respond to biologic therapies. An exciting new development is small molecule DMARDs targeting intracellular signalling pathways, which include Janus kinase (JAK) inhibitors. Other recent developments include a biologic DMARD that targets and suppresses the inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Rheumatoid Arthritis Content
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. This information is brought to you by Touch Medical Media and is not […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. This information is brought to you by Touch Medical Media and is not sponsored by, nor […]
Aurélie Najm, ACR 2021: B-cell Repertoire as a Predictor of Methotrexate Response
touchIMMUNOLOGY was delighted to speak with Dr Aurélie Najm (University of Glasgow, Glasgow, UK) about B-cell repertoire changes in patients with rheumatoid arthritis and the recent analysis designed to create a nomogram capable of using B-cell repertoire properties to predict response to methotrexate. This information is brought to you by Touch Medical Media and is […]
Gerd R. Burmester, ACR 2021: Long-term Sarilumab Treatment for Active Rheumatoid Arthritis
We were delighted to speak with Professor Gerd R. Burmester (Charité – Universitätsmedizin Berlin, Berlin, Germany) around the open label extension studies of sarilumab for the treatment of active rheumatoid arthritis (EXTEND: NCT01146652 and MONARCH: NCT02332590). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, […]
Andrea Rubbert-Roth, EULAR 2021: The Phase 3 SELECT-CHOICE Study
It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying […]
Roy Fleischmann, EULAR 2021: The Open-label Extension of the SELECT-COMPARE Study
TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis. ‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with […]
Peter Taylor, EULAR 2021: Coadministration of Filgotinib and Statins in Rheumatoid Arthritis
We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials. The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European […]
Anthony Sebba, ACR 2020 – Pain in Patients with Rheumatoid Arthritis (Part 3)
After his presentation at ACR 2020, we spoke with Anthony Sebba (Arthritis Associates, FL, USA) about the importance of studying pain as a patient reported outcome in rheumatoid arthritis and what further studies are needed. The abstract ‘Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!